BioSenic reacquires global IP rights and provides update on

INSIDE INFORMATION BioSenic plans to further develop its program on an active injectable viscosupplement JTA, combining anti-pain and anti-inflammatory characteristics on a subtype of knee... | May 17, 2023

Related Keywords

France , Walloon Region , Waals Gewest , Belgium , Mont Saint Guibert , Paris , France General , Hong Kong , French , Belgian , Neil Hunter Michelle Boxall , Ghislaine Gasparetto , Seitosei Actifin , Bert Bouserie , Annie Florence Loyer , Ib Communications , International Media Enquiries , Euronext Brussels , Marketing Authorization , Marketing Authorization Application , Chief Executive Officer , Arsenic Trioxide , Host Disease , Systemic Sclerosis , Louvain La Neuve Science Park , Mesenchymal Stromal Cells , Graft Versus Host Disease , Systemic Lupus , Chief Executive , Belgian Media , Investor Enquiries , French Media Enquiries , French Investor Enquiries , Biosenic Sa Stock Exchange , News , Information , Press Release , Inside , Biosenic , Plans , O , Urther , Evelop , Its , Program , N , Ctive , Injectable , Iscosupplement , Combining , End , Characteristics , Subtype , F Bios Be0974280126 ,